Emergent Biosolutions Inc (EBS) Company Profile & Statistics

Emergent Biosolutions Inc
EBS
(NYSE)
Closed
9.48
+0.08 (+0.85%)
in:usd•As of: Nov 22, 2024 15:59 UTC -5
After Market:9.49+0.01 (+0.10%)
Open
9.39
High
9.65
Low
9.38

About Emergent Biosolutions Inc

CEO

Joseph C. Papa

Headquarters

300 professional drive

gaithersburg, md 20879, united states

Auditor

Ernst & Young LLP

Employees

1,600

Share Holders

Website

www.emergentbiosolutions.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside of the U.S. BioThrax is the company's key Biodefense product, used for anthrax disease. The U.S. government is the primary purchaser of the company's Biodefense products. It supplies adjuvanted anthrax vaccine candidate, AV7909, to the U.S. government. It supplies smallpox vaccine ACAM2000, botulism therapeutic BAT, anthrax therapeutics 'raxibacumab & Anthrasil' and 3 other products to governments of different countries. It also retails 3 products Narcan nasal spray, Vaxchora and Vivoti. It provides contract development and manufacturing services to multiple pharma and biotech companies. The company has added key products Narcan nasal spray, ACAM2000, raxibacumab, Vaxchora and Vivoti through several acquisitions.

Emergent Biosolutions Inc Statistics

Valuation Measures

Market Capitalization ²	513.63M
Enterprise Value	1.02B
Enterprise Value/EBITDA (ttm)	-51.77
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	1.00
Price to Sales (ttm)	0.45
Price to Cash (ytd)	10.69

Profitability

Gross Margin (ttm)	31.74%
Operating Margin (ttm)	-4.86%
Profit Margin (ttm)	-21.74%
Return on Equity (ttm)	-9.91%
Return on Invested Capital (ttm)	-27.87%
Return on Assets (ttm)	-3.31%

Income Statement

Revenue (ttm)	1.13B
Revenue Per Share (ttm)	20.77
Gross Profit (ttm)	377.10M
EBITDA (ttm)³	-19.70M
Net Income Avi to Common (ttm)	-208.80M
Diluted EPS (ttm)	-4.10

Share Statistics

Beta (5Y Monthly)	1.57
52-Week Change	351.43%
S&P500 52-Week Change	30.93%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	54.18M
Dividend Yield	0.00%
Float ⁴	53.53M
% Held by Insiders	1.20%
% Held by Institutions	78.40%

Balance Sheet

Total Cash (mrq)	156.40M
Total Cash Per Share (mrq)	2.89
Total Debt (mrq)	662.60M
Total Debt/Equity (mrq)	130.33%
Current Ratio (mrq)	2.88%
Quick Ratio (mrq)	1.47%
Book Value Per Share (mrq)	9.40

Cash Flow

Operating Cash Flow Per Share (ytd)	2.49
Free Cash Flow (ytd)	125.00M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Emergent Biosolutions Inc

Trade With A Regulated Broker